{"id":"W2943108118","doi":"10.1093/annonc/mdz127","title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":488,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"Cilag; National Center for Advancing Translational Sciences; National Cancer Institute; Foundation Medicine; Ipsen; EMD Serono; Sanofi; Fidia Farmaceutici; Eisai; Astellas Pharma; Merck Sharp and Dohme; Genentech; GlaxoSmithKline; UroGen Pharma; Pfizer; Incyte; Exelixis; Kidney Cancer Association; Merck; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; AstraZeneca; Amgen","keywords":"Medicine; Docetaxel; Urothelial cancer; Paclitaxel; Pembrolizumab; Oncology; Internal medicine; Cancer; Chemotherapy; Randomized controlled trial; Bladder cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001823531,0.001765379,0.002639489,0.0003662493,0.000406395,0.001507421,0.001252388,0.001300866,0.008623991],"category_scores_gemma":[0.001439122,0.0007059237,0.002444499,0.0004068146,0.00124855,0.001348077,0.0005443951,0.003815369,0.001641877],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001511664,"about_ca_system_score_gemma":0.00129537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002304303,"about_ca_topic_score_gemma":0.005339848,"domain_scores_codex":[0.9993549,0.0003430779,0.00002629425,0.0001220174,0.00003513398,0.0001184882],"domain_scores_gemma":[0.9992509,0.0001737404,0.000200032,0.00008859492,0.00003967459,0.0002470072],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9682198,0.003838438,0.0008847999,0.0003932954,0.001862921,0.00004095151,0.00005742149,0.001087926,0.002398029,0.0002115468,0.002018242,0.01898679],"study_design_scores_gemma":[0.9370328,0.05584968,0.003353148,0.00003654811,0.0009812514,0.00005759472,0.0000516136,0.0006847979,0.0004548815,0.0002787348,0.001197854,0.00002114946],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836264,0.004421446,0.0007349712,0.001038819,0.0007480212,0.001683343,0.002916828,0.0001955782,0.004634693],"genre_scores_gemma":[0.9833152,0.001752315,0.001260934,0.001682881,0.000391143,0.001618868,0.003107832,0.00005222725,0.006818533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008623991,"threshold_uncertainty_score":0.02885014,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08149898714952458,"score_gpt":0.4267595225361745,"score_spread":0.3452605353866499,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}